Literature DB >> 2395090

Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method.

T Aoyama1, H Kotaki, Y Honda, F Nakagawa.   

Abstract

A gas chromatographic-mass spectrometric method was developed for the stereoselective quantification of threo-methylphenidate (MPD) and its metabolite, ritalinic acid (RA), in plasma or urine. The plasma concentrations of (+)-MPD after oral administration of two 10-mg conventional tablets containing racemic MPD.HCl or of 20-mg of racemic MPD.HCl crystals to two healthy subjects were much higher than those of the (-)-isomer. The plasma concentrations of the metabolite, (-)-RA, were higher than that of the (+)-isomer during the first 4 h after administration of racemic MPD.HCl in both tablet and crystal forms. Although in urine both (+)- and (-)-RA were largely excreted in 48 h (37 and 40% of the dose, respectively), the percentage excretion of (-)-RA during the first 3-4 h was approximately twice that of the (+)-isomer. These results suggest that one reason for the difference in the plasma levels between (+)- and (-)-MPD may be due to differences in their rates of metabolism. Pharmacokinetic parameters of (+)-MPD after administration of 10 mg of (+)-MPD.HCl crystals were almost the same as those after administration of racemic MPD.HCl crystals. The AUC infinity 0 of (-)-MPD after administration of 10 mg of (-)-MPD.HCl crystals was smaller than that after administration of racemic MPD.HCl crystals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2395090     DOI: 10.1002/jps.2600790602

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

Review 1.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

2.  Relationship among physicochemical properties, skin permeability, and topical activity of the racemic compound and pure enantiomers of a new antifungal.

Authors:  L Wearley; B Antonacci; A Cacciapuoti; S Assenza; I Chaudry; C Eckhart; N Levine; D Loebenberg; C Norris; R Parmegiani
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

Review 3.  Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.

Authors:  David J Heal; David M Pierce
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Effects of food on the pharmacokinetics of methylphenidate.

Authors:  K K Midha; G McKay; M J Rawson; E D Korchinski; J W Hubbard
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

5.  PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Authors:  Tyler Stevens; Katrin Sangkuhl; Jacob T Brown; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

6.  Enantioselective analysis of ritalinic acids in biological samples by using a protein-based chiral stationary phase.

Authors:  Jianhua Zhang; Yulin Deng; Jim Fang; Gordon McKay
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

7.  Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers.

Authors:  T Aoyama; H Kotaki; T Sasaki; Y Sawada; Y Honda; T Iga
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.

Authors:  N R Srinivas; J W Hubbard; E D Korchinski; K K Midha
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

9.  Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice.

Authors:  Aygul Balcioglu; Jia-Qian Ren; Deirdre McCarthy; Thomas J Spencer; Joseph Biederman; Pradeep G Bhide
Journal:  Neuropharmacology       Date:  2009-07-22       Impact factor: 5.250

Review 10.  Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.

Authors:  Mark L Wolraich; Melissa A Doffing
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.